Immupharma PLC Notification of Major Interest in Shares (2503K)
August 17 2012 - 4:11AM
UK Regulatory
TIDMIMM TIDMAV.
RNS Number : 2503K
Immupharma PLC
17 August 2012
FOR IMMEDIATE RELEASE 17 AUGUST 2012
NOTIFICATION OF MAJOR INTEREST IN SHARES
SHAREHOLDER CHANGE OF CONTROL
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
confirm that its long standing shareholder Aviva plc ("Aviva") has
recently notified the Company that it has transferred ImmuPharma
Ordinary Shares of 2,471,621, representing a 3.03% shareholding in
the Company, to Aviva Investors Global Services Limited (UK). This
shareholding had formerly been split into two indirect funds, BNY
Norwich Union Nominees Limited and Chase (GA Group) Nominees
Limited.
The full TR1 form is shown at the end of this announcement.
Commenting on the announcement, Richard Warr, Chairman said: "We
have recently commented that one of the Board's priorities is to
maintain and strengthen our blue chip shareholder base which we
believe will underpin ImmuPharma's true value in the long term. We
are therefore delighted that such a highly regarded institution as
Aviva continues to demonstrate its support for ImmuPharma and we
look forward to maintaining this long standing relationship with
Aviva and to build further value for shareholders in the
Company."
TR1 FORM
For filings with the FSA include the
annex
For filings with issuer exclude the
annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
-------------------------------------------------------------------------------------------------------
1. Identity of the issuer or the underlying Immupharma plc
issuer
of existing shares to which voting rights
are
attached:
------------------------------------------------------- ----------------------------------------------
2. Reason for the notification (please tick the appropriate box or boxes):
-------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
-------------------------------------------------------------------------------------------- ---------
An acquisition or disposal of qualifying financial instruments
which may result in the acquisition of shares already issued to
which voting rights are attached
-------------------------------------------------------------------------------------------- ---------
An acquisition or disposal of instruments with similar economic
effect to qualifying financial instruments
-------------------------------------------------------------------------------------------- ---------
An event changing the breakdown of voting rights
-------------------------------------------------------------------------------------------- ---------
Other (please specify): On market transfer between indirect and direct
funds
------------------------ ------------------------------------------------------------------ ---------
3. Full name of person(s) subject Aviva plc & its subsidiaries
to the
notification obligation:
-------------------------------------------- ---------------------------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):
BNY Norwich Union Nominees Limited
220,000*
Chase (GA Group) Nominees Limited 2,251,621*
*denotes direct interest
-------------------------------------------- ---------------------------------------------------------
5. Date of the transaction and date 14 August 2012
on
which the threshold is crossed or
reached:
-------------------------------------------- ---------------------------------------------------------
6. Date on which issuer notified: 16 August 2012
-------------------------------------------- ---------------------------------------------------------
7. Threshold(s) that is/are crossed <3% to 3% change at Direct Interest
or Level
reached:
-------------------------------------------- ---------------------------------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the triggering
of to the triggering transaction
shares transaction
if possible
using
the ISIN CODE
--------------- ---------------------------------- -----------------------------------------------------------------
Number Number Number Number of voting % of voting rights
of of of shares rights
Shares Voting
Rights
--------------- ---------------- ---------------- ---------- -------------------------- -------------------------
Direct Direct Indirect Direct Indirect
--------------- ----- --------- ----- --------- ---------- ------------ ------------ --------- --------------
Ordinary
Shares
Not
GB0033711010 Not Disclosable Not Disclosable 2,471,621 2,471,621 3.03% Disclosable
---------------- ---------------- ---------- ------------ ------------ --------- --------------
Not
Disclosable
----------------------------------------------- ---------- ---- ------ ------------ ---- --- --------------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion Period rights that may rights
be
acquired if the
instrument is
exercised/ converted.
---------------------- ---------------- --------------------------- -------------------------- -------------------
C: Financial Instruments with similar economic effect to Qualifying Financial
Instruments
----------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting rights
instrument price date Conversion rights instrument
period refers to
------------------ --------- ----------- ------------ ------------------- ---------------------
Nominal Delta
------------------ --------- ----------- ------------ ------------------- ----------- --------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
2,471,621 3.03%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held, if applicable:
-------------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva Investors Global
Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
-------------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
----------------------------------------------------- ------------------------------
11. Number of voting rights proxy holder will
cease
to hold:
----------------------------------------------------- ------------------------------
12. Date on which proxy holder will cease to
hold
voting rights:
----------------------------------------------------- ------------------------------
13. Additional information:
---------------------------------------- -------------------------------------------
14. Contact name: Tracy Weimar, Vice President Operations
and Company Secretary
---------------------------------------- -------------------------------------------
15. Contact telephone number: 020 7152 4080
---------------------------------------- -------------------------------------------
Ends
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Dr Robert Zimmer, President +33 389 66 13 20
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Executive Chairman + 44 7766 232747
Lisa Baderoon, Head of Investor Relations +44 7721 413 496
Buchanan + 44 20 7466 5000
Mark Court
Panmure Gordon & Co +44 20 7459 3600
Andrew Burnett, Fred Walsh
Cenkos Securities +44 20 7397 8900
Stephen Keys, Camilla Hume (Corporate
Finance)
Andy Roberts (Sales)
Espirito Santo Investment Bank +44 20 7456 9191
James Bromhead, Richard Crawley
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has recently received the
approval from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. ImmuPharma was founded and
is led by a commercially focused Board and management team with
extensive experience. www.immupharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLLIFITTAIDLIF
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
